Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yhim, H-Y | - |
dc.contributor.author | Kim, K. | - |
dc.contributor.author | Kim, J. S. | - |
dc.contributor.author | Kang, H. J. | - |
dc.contributor.author | Kim, J-A | - |
dc.contributor.author | Min, C-K | - |
dc.contributor.author | Bae, S. H. | - |
dc.contributor.author | Park, E. | - |
dc.contributor.author | Yang, D-H | - |
dc.contributor.author | Suh, C. | - |
dc.contributor.author | Kim, M. K. | - |
dc.contributor.author | Mun, Y-C | - |
dc.contributor.author | Eom, H. S. | - |
dc.contributor.author | Shin, H. J. | - |
dc.contributor.author | Yoon, H-J | - |
dc.contributor.author | Kwon, J. H. | - |
dc.contributor.author | Lee, J. H. | - |
dc.contributor.author | Kim, Y. S. | - |
dc.contributor.author | Yoon, S-S | - |
dc.contributor.author | Kwak, J-Y | - |
dc.date.available | 2020-02-29T00:43:37Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2013-03 | - |
dc.identifier.issn | 0268-3369 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14715 | - |
dc.description.abstract | The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic chemotherapy alone on disease outcome. Data from 48 patients who underwent second auto-SCT were matched to 144 patients (1:3) who received systemic chemotherapy alone from the Korean Myeloma Registry. Groups were matched for nine potential prognostic factors and compared for treatment outcomes. The median age of matching-pairs at relapse was 55.5 years. A total of 156 patients (81%) received vincristine, doxorubicin and dexamethasone induction therapy before the first auto-SCT. Thirty-five patients (73%) in the second auto-SCT group received novel agent-based therapies before the second auto-SCT, and similar proportion in both groups received novel therapies after relapse of front-line auto-SCT. With a median follow-up of 553 months, patients who underwent a second auto-SET had significantly better median OS (55.5 vs 25.4 months, P=0.035). In multivariate analysis for OS, <18 months time to progression after first auto-SCT, International Staging System III and salvage chemotherapy alone were independent predictors for worse OS. The outcomes of second auto-SCT appear to be superior to those of systemic chemotherapy alone. A randomized trial comparing both treatment strategies is required. Bone Marrow Transplantation (2013) 48, 425-432; doi:10.1038/bmt.2012.164; published online 3 September 2012 | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.relation.isPartOf | BONE MARROW TRANSPLANTATION | - |
dc.subject | STEM-CELL TRANSPLANTATION | - |
dc.subject | LENALIDOMIDE PLUS DEXAMETHASONE | - |
dc.subject | HIGH-DOSE CHEMOTHERAPY | - |
dc.subject | ALLOGENEIC TRANSPLANTATION | - |
dc.subject | BORTEZOMIB | - |
dc.subject | SURVIVAL | - |
dc.subject | THERAPY | - |
dc.subject | AUTOGRAFT | - |
dc.subject | DURATION | - |
dc.title | Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000316920100017 | - |
dc.identifier.doi | 10.1038/bmt.2012.164 | - |
dc.identifier.bibliographicCitation | BONE MARROW TRANSPLANTATION, v.48, no.3, pp.425 - 432 | - |
dc.identifier.scopusid | 2-s2.0-84875222958 | - |
dc.citation.endPage | 432 | - |
dc.citation.startPage | 425 | - |
dc.citation.title | BONE MARROW TRANSPLANTATION | - |
dc.citation.volume | 48 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Lee, J. H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | auto-SCT | - |
dc.subject.keywordAuthor | multiple myeloma | - |
dc.subject.keywordAuthor | salvage therapy | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | LENALIDOMIDE PLUS DEXAMETHASONE | - |
dc.subject.keywordPlus | HIGH-DOSE CHEMOTHERAPY | - |
dc.subject.keywordPlus | ALLOGENEIC TRANSPLANTATION | - |
dc.subject.keywordPlus | BORTEZOMIB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | AUTOGRAFT | - |
dc.subject.keywordPlus | DURATION | - |
dc.relation.journalResearchArea | Biophysics | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Transplantation | - |
dc.relation.journalWebOfScienceCategory | Biophysics | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Transplantation | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.